Replies to post #185790 on Biotech Values

[DewDiligence]

Re: GLPG.BR director resignation

I don't know of any partnership with BMY, and I'm not familiar [enough] with BMY to know if there are competing programs, but I imagine some may have been speculating on something else going on.

I wouldn’t infer that something is going on. A simpler explanation is that Galapagos is trying to comply with the one of the tenets of contemporary corporate governance: eschewing directors who have multiple directorships or time commitments to other companies that could compromise the performance of their oversight duties.

p.s. Sato is also a director of PKI.